proposed policy topics for statement development by the apha policy committee
Post on 21-Jan-2016
Embed Size (px)
DESCRIPTIONProposed Policy Topics for statement development by the APhA Policy Committee. Moderator: Bradley P. Tice, PharmD, MBA, FAPhA Speaker, APhA House of Delegates. For Your Information. Please submit your thoughts on the policy topics throughout the webinar or send them to HOD@aphanet.org - PowerPoint PPT Presentation
Moderator:Bradley P. Tice, PharmD, MBA, FAPhASpeaker, APhA House of Delegates
Please submit your thoughts on the policy topics throughout the webinar or send them to HOD@aphanet.orgIf you are using a phone line to listen, please dial 415-655-0062; Access Code: 856-377-400. Be sure to include your Audio PINTo request to speak, click on the raise hand tab and you will be placed in the queue. The comments we take or mention on the webinar may be limited due to time. However, all comments will be provided to the Policy Committee for use in their deliberations.The moderator will clarify issues but will not engage in debate.Remember, be courteous to your colleagues in your communications.
To provide an opportunity for member input on policy topics prior to the proposed statement development by the Policy Committee
To promote the early engagement of Delegates on the development and submission of quality new business items on topics not assigned to the Policy Committee
To generate Delegate interest in Policy and House-related committees as part of the policy development process
Review the purpose of the House of Delegates
Review the policy development process
Review 2013 proposed policy topics and gain perspectives on the issues
Generate interest and solicit names for House Committees
Webinar scheduled for 90 minutes.10 minutes for intro, 20 minutes per topic, 20 minutes for final comments
House of Delegates serves as a legislative body in the development of ASSOCIATION policy. It shall act on such policy recommendations as shall come before it and shall adopt rules or procedures for the conduct of its business. (from APhA Bylaws) Association PolicyAdvocacy ActivitiesExternal CommunicationsAdvisory CommitteesAssociation Activities
House of Delegates Policy CommitteesPolicy CommitteePolicy Review Committee Policy Reference CommitteeNew Business Review CommitteeHouse Rules Review Committee
House of Delegates Election Committees (every other year)Committee on Nominations Committee of Canvassers
50 states plus DC, Guam, and Puerto Rico12 National Pharmacy OrganizationsAAPS, AACP, ACA, ACCP, AIHP, AMCP, ASHP, ASCP, ASPL, NCPA, National Pharmaceutical Association, National Pharmacists Association5 Federal Pharmacy GroupsAir Force, Army, Navy, PHS, VAAPhAAcademies: APPM, APRS, ASPBoard of TrusteesFormer PresidentsFormer Speakers
Thomas E. Menighan, BS Pharm, MBA, ScD (Hon), FAPhASecretary, APhA House of Delegates APhA Executive Vice President & CEOAPhA Board of Trustees
Bradley P. Tice, PharmD, MBA, FAPhASpeaker, APhA House of DelegatesAPhA Board of Trustees
William H. Riffee, PhDSpeaker - Elect, APhA House of Delegates
Topic GenerationIdeas obtained from Delegates, Members, State Pharmacy Associations, Committees, Trustees, Staff, and Surveys43 topic submissions received Recommendations by APhA-APPM/APRS/ASP Joint Policy Standing CommitteeBackground on issues and potential direction assembledTopic Prioritization Committee discussed the top 15 topicsFurther discussed top 15, topics combined, and then ranked top 3Refined direction of top 3 by answering key questions
What is the problem?Why is it a problem?What are the issues that need to be addressed?
1. Expanding Access to Pharmaceuticals
2. Ensuring Access to Pharmacists Services (Role of payers and providers in Patient Care)
3. Medication Take Back/Disposal Programs
APhA StaffAPhAHouse of Delegates APhAMembersSurveys, OtherAPhA-APPM/APRS/ASPJoint Policy Standing CommitteeAPhAHouse of DelegatesPolicy Committee PROPOSED Policy StatementAPhA-APPM/APRS/ASPJoint Policy Standing CommitteeImplementation IDEAS For Policy StatementsAPhABoard of TrusteesACTIONAPhAHouse of Delegates APhABoard of TrusteesState AssociationsIDEAGACYOU!WebinarIDEAIDEAWebinarADOPTEDPolicy Statements
Setting the stageCurrent drug classification systemRx and OTC (some state variances)Role / Involvement of pharmacists is variableAccess by patients to some pharmaceuticals restrictedPractice actsInsuranceAccess to care provider
Summary of Key ConceptsFinancial constraints / shortage of primary care physiciansGrowing interest in increasing accessPharmacists have knowledge / skills When pharmacists are more involved in patient care, health outcomes improve and costs go down.FDA is considering a new paradigm of medication useReluctance among the physician community and some consumer groups that the new paradigm will sever the patient-physician relationship.Concern with use of vending machines, that are resulting in patients purchasing prescription and behind-the-counter medications without access to a pharmacist.
Potential ScopeSupporting the creation of an OTC+ or Conditions of Safe Use category of drugs which require pharmacist interventionBehind the counter and vending machine distribution of medications (EC)Stress importance of patients having access to beneficial medications and access to pharmacists services
What are the issues that a proposed policy statement should address and what are your suggested directions that the Policy Committee should consider in crafting proposed policy language?Overall importance of patient access to pharmacistsOTC+Support opportunities for pharmacists to assume patient care roles, including OTC+Support updating state and federal laws/regulations to require access to pharmacists Need some pilotsWhich prescription medications (or categories), if any, are appropriate for the OTC+ concept?What drug categories should be included; that we support the process, include monitoring and follow-up; could incorporate adherence for chronic disease medications.Opportunity to increase access and decrease costWay to loop people back into the healthcare system (coordination and collaboration)Coordination with payers for payment and quality measuresWay to improve quality ratingsAddress concerns raised by other health professions
What are the issues that a proposed policy statement should address and what are your suggested directions that the Policy Committee should consider in crafting proposed policy language?How should vending machine distribution be controlled to ensure patient safety?Are there features that should be included (access to pharmacist?)Are there medications that should not be distributed via this mechanism?
What are your thoughts?
Potential Scope of Proposed PolicyWhat is preventing pharmacists from performing medication therapy management (MTM) or other patient care services?Are there system issues impacting this?What is preventing payers from incentivizing or encouraging pharmacists to perform MTM or other patient care services?Are there practice issues creating barriers?
What Is The Problem? What are the issues that a proposed policy statement should address and what are your suggested directions that the Policy Committee should consider in crafting proposed policy language?Health benefit data (medical and pharmacy) should be connectedlook at pharmacoeconomic and overall healthcare costs.Decisions need to be pursuant to evidence-based dataCMS standards for MTM programs and contracting directly with providers
What Is The Problem? What are the issues that a proposed policy statement should address and what are your suggested directions that the Policy Committee should consider in crafting proposed policy language?OthersPrior authorization programs and formulary management policies can create barriers to patient carePayment to pharmacists by insurance and PBMs for medication management/patient care servicesPBM transparencyPharmacy overregulationAccountability of PBMs regarding the MTM benefit administration and the scope of benefitsProvider status recognition and network inclusion
What are your thoughts?
Potential ScopePharmaceuticals and Personal Care Products in the EnvironmentsLook at 2012 APhA-ASP policyDevelop and implement standardized guidelines for the proper disposal of unused or expired medications that help prevent drug abuse and reduce harm to the environment. (Source: APhA-ASP 2012.3 Proper Medication Disposal and Drug Take-Back Programs)Allow pharmacies to take back unused or expired medications, including controlled substances, through a process that minimizes diversion, liability, and financial burden to all stakeholders. (Source: APhA-ASP 2012.3 Proper Medication Disposal and Drug Take-Back Programs)Encourage pharmacists and student pharmacists to serve as a source of information for the public on the proper disposal of unused or expired medications. (Source: APhA-ASP 2012.3 Proper Medication Disposal and Drug Take-Back Programs)
2009 Medication Disposal1. APhA encourages appropriate public and private partnerships to accept responsibility for the costs of implementing safe medication disposal programs for consumers. Further, APhA urges DEA to permit the safe disposal of controlled substances by consumers.2. APhA encourages provision of patient appropriate quantities of medication supplies to minimize unused medications and unnecessary medication disposal.(JAPhA NS49(4):493 July/August 2009)
What are the issues that a proposed policy statement should address and what are your suggested directions that the Policy Committee should consider in crafting proposed policy language?Uniform disposal guidelines that align requirements for state and federal laws and regulations for pharmacists and patientsDisposal of medications and hazardous pharmaceuticals and materialsSafety in the household; lack of effective and available medication take back systems and programs in the community and through local pharmacie